BIIB022

Biogen · Phase 1 active Small molecule

At a glance

Generic name	BIIB022
Also known as	IGF-1R, Liver Cancer, Hepatocellular Carcinoma, Monoclonal Antibody, Sorafenib
Sponsor	Biogen
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

BIIB022 CI brief — competitive landscape report
BIIB022 updates RSS · CI watch RSS
Biogen portfolio CI